Polyethylene glycol-conjugated (PEG) asparaginase is approved for use in patients who develop allergy to other forms of asparaginase, although its ability to deplete asparagine systemically in patients with hypersensitivity has not been well elucidated. In 53 children with newly diagnosed acute lymphoblastic leukemia, we serially assessed asparagine concentrations in cerebrospinal fluid (CSF) and plasma as well as serum anti-asparaginase antibodies. All patients received native Escherichia coli (Elspar) asparaginase during induction therapy; patients received PEG asparaginase during reinductions when available, and those who developed allergy received Erwinia asparaginase. All eight patients who developed clinical evidence of allergy to asparaginase had anti-asparaginase antibodies. Among patients who had no antibodies, those who received E. coli had lower mean (7s.d.) CSF asparagine (0.2970.63, n ¼ 9) than those who received PEG (0.7770.82, n ¼ 4) (P ¼ 0.007). Results were similar for plasma asparagine. There was no situation where asparagine concentrations were more effectively depleted by PEG than by other preparations. None of the five patients who developed thrombosis had an allergy or antibodies to asparaginase at the time of the thrombosis. We conclude that asparagine concentrations were less effectively depleted by PEG than by E. coli asparaginase at the doses commonly used. The risk of thrombosis may be affected by the intensity of asparaginase exposure.
Introduction
The overall survival rate in children with acute lymphoblastic leukemia (ALL) is now approximately 80%, using multidrug regimens. 1 Asparaginase has been associated with improved results in the Dana Farber studies, 2 and is used in remission induction and other phases of therapy. 3, 4 Asparaginase hydrolyzes asparagine to aspartic acid and ammonia in extracellular fluid. 5 Although most normal cells can synthesize asparagine, inducibility of asparagine synthetase activity is diminished in some malignant lymphoblasts, and these leukemic cells require exogenous asparagine. Asparaginase reduces asparagine-dependent protein synthesis, and inhibits nucleic acid synthesis, resulting in leukemic cell death. 6 Asparaginase products currently in use in the United States are derived from Escherichia coli (eg Elspar s , Merck & Co., West Point, PA, USA) or Erwinia chrysanthemi (eg Erwinase).
Polyethylene glycol (PEG) conjugate of E. coli asparaginase (eg Oncospar s ) has been approved for use in patients who are allergic to 'native' forms of asparaginase, although its relative efficacy in depleting asparagine remains uncertain. 3, [7] [8] [9] The development of anti-asparaginase antibodies has been linked to the inactivation of asparaginase, thereby attenuating its ability to deplete asparagine systemically, and putatively compromising its antileukemic effects. Anti-asparaginase antibodies occur in as many as 70% of children receiving E. coli asparaginase. 3, [10] [11] [12] The best course of action, including the use of premedications and substitution with PEG, or Erwinia asparaginase, in cases with frank or silent hypersensitivity to E. coli asparaginase, is also not clear.
In a front-line ALL trial, we serially assessed plasma and cerebrospinal fluid (CSF) asparagine, along with serum antibodies to all three asparaginase preparations available in the United States, to determine whether asparagine depletion varied with antibody status and asparaginase preparation, and we explored whether asparagine measures correlated with risk of thrombosis.
Methods

Patient eligibility and treatment schedules
All patients enrolled on the St Jude Children's Research Hospital Total XIV protocol for children with newly diagnosed ALL 13 were serially assessed for concentrations of asparagine in the CSF and in plasma, as well as for the presence of antiasparaginase antibodies in serum (Figure 1 
Sample collection
CSF samples were collected when diagnostic lumbar punctures or IT chemotherapy treatments were scheduled, including preasparaginase therapy, and at days 5, 26, and 33 of induction and concurrent with IT therapy during reinduction treatments ( Figure 1 ). CSF was collected in tubes containing sulfosalicylic acid (10 mg/ml final concentration) to deproteinize the sample immediately and to prevent protein degradation to amino acids. The sample was kept on ice, and centrifuged at 10 000 g for 15 min. The supernatant was stored at À701C until analysis. Blood samples for plasma asparagine concentrations were collected in heparinized tubes, immediately placed on ice and centrifuged in a refrigerated centrifuge at 2500 g for 3 min. Plasma was immediately removed, deproteinated by using an ultrafiltration membrane (Millipore, Centrifree YM-30, Billerica, MA, USA) at 3000 g for 1 h at 41C, and stored at À701C until analysis.
Blood samples for anti-asparaginase antibodies were collected in red-topped tubes, centrifuged at 2500 g for 10 min, and the serum was stored at À701C until analysis. Patients were tested for antibodies against all three preparations, (E. coli, Erwinia, and PEG), at baseline (before therapy began), and at the end of remission induction, reinduction I, and reinduction II.
Analytical methods
Asparagine concentrations in CSF and plasma were determined by an ion-exchange chromatography method using postcolumn derivitization with o-phthaldialdehyde (Beckman, part # 338048) and fluorescent detection. Separation was made on a spherogel column (Beckman, part # 239428). The isocratic mobile phase was 0.2 N Li þ buffer with pH 4.8. D-glucosaminic acid (Sigma, cat # G-0259) was used as an internal standard. Fluorescence detection was conducted at lEmission ¼ 430 nm and lExcitation ¼ 330 nm. The detection limit of asparagine was o0.025 mM and the limit of quantification was set to 0.05 mM. An amino-acid standard solution (Beckman part # 338088 and 338156) was used as an initial calibration. Three CSF or plasma controls for high concentration (10 mM), medium concentration (1.0 mM), and low concentration (0.025 mM) were measured daily with the sample analysis. The coefficients of variations were approximately 10% for interday assays and 5% for intraday assays.
Anti-asparaginase antibody levels were measured by ELISA as previously reported by Wang et al.
14 E. coli (5 mg/ml Elspar, Lot No. 0860D, Merck & Co., West Point, PA, USA), Erwinia (5 mg/ ml, Lot No. 1009H6E , MRA/CAMR, Salisbury, UK), and PEG (10 mg/ml, Oncospar, Lot No. A02603, Enzon, Inc., Piscataway, NJ, USA) were coated in the wells of the plate. Patient plasma samples were then added and incubated for 1 h, after which a polyclonal goat anti-human IgG horseradish peroxidase conjugate was added and incubated for 1 h. After washing, ophenylenediamine dihydrochloride was added and incubated for 30 min. Anti-asparaginase antibody levels were measured at 490 nm for the enzymatic product (subtracting the absorbance at 650 nm for nonspecific absorbance) using a microplate reader. The antibody levels are recorded as the mean of the optical density (OD) readings from duplicate wells.
Statistical analysis
This study required a number of two-sample comparisons between cohorts defined by the development of thrombosis or not, development of allergy or not, development of antibody or not, etc. Owing to the small sample sizes, the exact Wilcoxon's rank-sum test was used for all two-sample comparisons. 15 Comparisons of proportions in 2 Â 2 tables were made by Fisher's exact test. 16 All statistics were computed using the statistical software SAS (The SAS Institute, Cary, NC, USA). Owing to the exploratory nature of this study, no adjustment for multiple testing was made. Results are expressed as mean7 standard deviation (s.d.).
Results
A total of 53 children were enrolled on the study (Table 1) . Asparaginase was given to all patients during induction, 46 during reinduction I and 43 during reinduction II. Eventually, eight patients had clinical signs of asparaginase allergy and all of these patients had anti-asparaginase antibodies to E. coli prior to or at the first time point assayed after their clinical allergy. By the end of reinduction II, 11 of 31 (35.5%) of patients tested who had not experienced clinical allergy had 'silent hypersensitivity,' with serum antibodies to E. coli asparaginase.
Of the 19 patients who had antibodies to the E. coli asparaginase (Elspar) at some point in therapy, 13 patients also had antibodies to PEG asparaginase at some point in therapy, but only eight of these 13 patients had actually received PEG asparaginase. No patient had antibodies to Erwinia asparaginase until they were exposed to this preparation. Of the seven patients who were switched to receive Erwinia asparaginase, two developed antibodies to the Erwinia preparation. Schema of therapy and sampling for CSF and serum. The arrows indicate the times when CSF and plasma were collected for measurement of asparagine, the asterisks indicate the times when serum was collected for measurement of anti-asparaginase antibodies. CSF, but not plasma, concentrations of asparagine measured at the end of the remission induction treatment period were lower in patients who received nine rather than six doses of E. coli asparaginase (P ¼ 0.0332 and 0.634, respectively, Figure 2 ). There was a weak correlation between simultaneous CSF and plasma concentrations at the end of reinduction I (r ¼ 0.46965, P ¼ 0.0029), and at the end of reinduction II (r ¼
Asparagine: end of induction
All patients received only E. coli asparaginase during induction, and only one patient had an allergic reaction during induction.
Among the patients without allergy, the CSF asparagine level (3.5874.03 mM) at the end of induction in the four patients who had anti-asparaginase antibodies was comparable (P ¼ 0.64) to that of the 36 patients (3.2977.11 mM) who did not have antibodies (Table 2, Figure 3) . Likewise, plasma asparagine was not significantly different between the six patients who had antiasparaginase antibodies at the end of remission induction (20.39716.89 mM) and the 40 patients who did not have antibodies at the end of the induction phase (13.27723.0 mM) (Wilcoxon's two-sample test, P ¼ 0.31).
Asparagine: end of reinduction I
Among patients who had no allergy to this point and were also antibody negative, CSF asparagine was lower in the nine patients who received only E. coli asparaginase (mean7s.d., 0.2970.63 mM; P ¼ 0.007) than in the 14 patients who were treated only with PEG asparaginase during reinduction I (0.7770.82 mM) (Table 3 ) (Figure 3 ).
Among patients who had no allergy to this point but were antibody positive (ie silent hypersensitivity), CSF asparagine was comparable (P ¼ 0.20) in the six patients who received only E. coli asparaginase (1.7571.94 mM) and the four patients who only received PEG asparaginase during reinduction I (7.3977.66 mM) (Table 3) (Figure 3) .
Among the five patients who had an allergy by the end of reinduction I (all of whom also had antibodies by that time), three patients received E. coli asparaginase and then switched to Erwinia asparaginase. In these patients, the asparagine concentration in the CSF was 2.5972.05 mmol and in the plasma was 9.53716.59 mM. In one patient who received PEG asparaginase and then Erwinia asparaginase, asparagine concentration in the CSF was 1.24 mM (Table 3 ) and in the plasma it was undetectable; asparagine levels were not measured in the fifth patient.
Asparagine: after reinduction II
Among patients who had no allergy to this point and were also antibody negative, CSF asparagine was comparable (P ¼ 0.15) between the four patients who received only E. coli asparaginase (0.1570.21 mM) and the five patients who were treated only with PEG asparaginase during reinduction II (0.5570.41 mM) (Table 3) (Figure 3 ).
Among patients who had no allergy to this point but were antibody positive (ie subclinical hypersensitivity), CSF asparagine was comparable (P ¼ 0.79, Wilcoxon's two-sample test) between the two patients who received only E. coli asparaginase (1.1170.17 mmol) and the three patients who only received PEG asparaginase during reinduction II (2.4672.09) ( Table 3) .
Among the patients who had an allergy by the end of reinduction II (all of whom also had antibodies by that time), the two patients who received E. coli followed by Erwinia asparaginase had an asparagine concentration of 0.987 0.67 mM in the CSF and undetectable in the plasma. In one patient who received PEG asparaginase followed by Erwinia asparaginase, asparagine concentration in the CSF was 4.49 mM (Table 3) .
Thrombosis
Thrombosis developed in five patients: three after induction, one after reinduction I, and one after reinduction II. None of the five patients who developed thrombosis had clinical signs of allergy or had antibodies to asparaginase prior to thrombosis.
Figure 2
Comparison of CSF and plasma asparagine levels in patients who received six vs nine doses of asparaginase (all E. coli) during remission induction. (CSF, P ¼ 0.03; plasma, P ¼ 0.63). 
Discussion
Asparaginase has been shown to improve the outcome in children with ALL and is used in remission induction and most reinduction regimens. 3, 17 Modest differences in scheduling or preparations of asparaginase have been associated with significant differences in cure rates and toxicity. 3, 18, 19 Native E. coli preparations have been the most commonly used form of the drug in newly diagnosed patients with ALL; however, when these patients develop hypersensitivity, the relative efficacy of PEG, Erwinia, or native E. coli asparaginase in depleting asparagine is not known. In this study, our aim was to assess serially whether asparagine depletion varied with anti-asparaginase antibody status during treatment with three different asparaginase preparations. It is important to note that this was not a randomized study, as all patients received native E. coli during induction. Owing to the small number of patients in this study, it is possible that some of the differences might have been related to patient characteristics rather than the particular asparaginase preparation given, but we were unable to demonstrate a benefit of the use of PEG asparaginase at the dose commonly used in patients with or without clinical hypersensitivity or silent antibodies. At the end of both reinductions I and II, median CSF asparagine concentrations were always higher in patients who received PEG asparaginase. In antibody-positive patients, PEG was not better than E. coli in depleting CSF asparagine concentrations, and PEG was, in fact, worse than E. coli in antibody-negative patients. Similarly, plasma asparagine levels were always higher in patients with allergy who received PEG asparaginase as compared to those receiving E. coli or Erwinia asparaginase at the end of reinductions I and II treatments. Although the number of patients was very small, asparagine levels tended to be lower in patients treated with Erwinia than in those who received PEG (Figure 4) .
PEG asparaginase was approved in the US in 1994 'for the treatment of patients with ALL who are hypersensitive to native forms of L-asparaginase (http://www.fda.gov/cber/products/pegaenz020194.htm). However, there are few published data on the efficacy of PEG asparaginase in precisely this situation. 20 Herein, we demonstrate that, using asparagine depletion as an indicator of efficacy, PEG asparaginase at the dose of 2500 U/m 2 weekly was not more effective than E. coli or Erwinia asparaginase. It should be noted that the dose used in this study is in fact higher than the dose recommended by the manufacturer (ie 2500 U/m 2 every 14 days), and many patients received PEG had no evidence of allergy or antibodies.
Similar to our previous reports, 11,21 the development of antibodies was more common in patients with clinical signs of allergy, but antibodies were also common in those without clinical signs of allergy. All of the patients with allergy developed antibodies, while 35% of patients without allergy had measurable antibodies. Our data support the finding that Figure 3 CSF asparagine in patients who had no allergy up to the points of measuring asparagine at the end of induction and the end of reinduction I, grouped by antibody status and by asparaginase formulation. The asparaginase dosing refers to the asparaginase for that course (reinduction I or II, respectively). plasma levels of asparagine are higher in patients who develop antibodies to asparaginase compared to those without antibodies. 3 This effect was seen for every treatment period, either in plasma or CSF. (Table 2 ) This report also confirms our previous findings of crossreactivity of serum antibodies to three sources of asparaginase antigens: E. coli, Erwinia, and PEG. 22 After reinduction II, of the 13 patients who had developed antibodies to PEG, five of them had not received PEG. In contrast, no patients had positive serum antibodies against Erwinia unless they had received Erwinia asparaginase.
Several patients received three additional doses of asparaginase during remission induction according to the protocol because they had residual blasts at day 19 of therapy ( Figure 3) . The lower CSF concentrations in these patients who received nine as compared to those treated with six doses suggest that asparaginase therapy may contribute to effective CNS control, and that despite relatively intensive asparaginase during remission induction, the incremental increase in doses had additional pharmacologic effect.
Recently, Avramis et al 23 reported the experience of the Children's Cancer Group, in which 118 patients were randomly assigned to receive 2500 IU/m 2 of PEG asparaginase i.m. on day 3 of induction and each of two delayed intensification (DI) phases or 6000 IU/m 2 of native asparaginase i.m. three times per week for nine doses during the same phases. There were significantly more bone marrow aspirates with o5% lymphoblasts at days 7 and 14, and lower antibody levels to E. coli asparaginase at the end of induction and the first DI in patients treated with PEG than in those with native asparaginase. These data are clearly different from the findings in the current study where PEG dose intensity was higher during each reinduction phase but was not shown to be better than E. coli in depleting asparagine. One possible explanation might be that native asparaginase is more antigenic than PEG and, as we have recently reported, 22 these antibodies crossreact with PEG to blunt its activity even when PEG is given in higher doses. It is possible that even higher doses of PEG should be used in patients who have previously been exposed to E. coli asparaginase. In the Avramis study, with continued therapy during the second DI phase, the antibody levels were similar for both agents, and there was a trend toward lower serum or CSF asparagine concentrations for native asparaginase. Taken together with the data presented herein, it appears that one cannot extrapolate findings based on the use of PEG asparaginase 'up-front' with those observed when PEG asparaginase is used after E. coli asparaginase, at least with regard to its ability to deplete asparagine, and possibly, any benefit of PEG asparaginase seen early in therapy might diminish over time.
Thrombosis after asparaginase therapy occurs in 2.5-15% of patients. 24, 25 We observed thromboses in five patients, none of whom had clinical signs of allergy nor had they developed antibodies to asparaginase. These data are consistent with the notion that the risk of thrombosis may be higher in those with highest exposure to active asparaginase. 26, 27 These data support our practice to substitute Erwinia asparaginase in patients who develop clinical hypersensitivity to native E. coli, asparaginase, and raise the concern of using PEG asparaginase (at the currently recommended dose) in this situation. It remains uncertain whether patients with subclinical hypersensitivity should receive an alternative asparaginase preparation even in the absence of clinical allergy. Unfortunately, shortages of all forms of asparaginase continue to complicate the design of asparaginase regimens in the treatment of children with ALL. As asparaginase has significant impact on the outcome in ALL, clinical pharmacologic studies of this class of agent remain necessary.
